Travere Therapeutics Inc (NAS:TVTX)
$ 6.16 -0.18 (-2.84%) Market Cap: 468.95 Mil Enterprise Value: 431.93 Mil PE Ratio: 0 PB Ratio: 6.33 GF Score: 54/100

Travere Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 03:00PM GMT
Release Date Price: $18 (-6.93%)
Maury Raycroft
Jefferies - Analyst

(audio in progress) Raycroft, and I'm one of the Biotech Analysts at Jefferies. It's with great pleasure that I'd like to welcome our guests today, Eric Dube, President and CEO of Travere, and Peter Heerma, the CCO of Travere. Thanks so much for joining us today.

Eric Dube
Travere Therapeutics, Inc. - President and CEO

Thanks for having us.

Maury Raycroft
Jefferies - Analyst

And we're going to do a fireside chat format. So maybe for those who are new to the story, if you could provide a one-minute intro [of future there]?

Eric Dube
Travere Therapeutics, Inc. - President and CEO

Sure. So Travere Therapeutics is a company based in San Diego, exclusively focused on rare disease. We have an established commercial portfolio and infrastructure that's been focused on rare kidney and liver disease for a number of years that we've now used really to establish what is in the early days of a successful launch of sparsentan or FILSPARI in IgA

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot